Antibody-Based Therapeutics: Where Are We and Future Perspectives?
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 442
Special Issue Editors
Interests: antibody structure, analysis and design; human antibody repertoire; vaccines; therapeutic antibodies; history of immunology
Interests: monoclonal antibodies; antibody engineering; antibodies; phage display; recombinant protein expression; recombinant antibodies; tumor angiogenesis; immunohistochemistry; flow cytometry; immunofluorescence; cloning; cell culture; targeted therapeutics
Interests: antibody isolation; phage display; therapeutic protein; upstrem process development; transgenic techniques; recombinant protein expression; cell line engineering; antibody discovery; protein engineering
Special Issue Information
Dear Colleagues,
There is a growing interest in the use of immunotherapy approaches for the treatment of cancer, which has been promoted by the clinical results obtained against various types of malignancies using anti-PD-1 and anti-PD-L1 antibodies.
The activation of the immune system for a selective removal of tumor cells is the goal of this therapeutic approach, which can be achieved by using two classes of bifunctional products: (i) antibody-based targeted therapeutics (e.g., antibody–cytokine fusions) and (ii) bispecific antibodies.
Antibody-based cytokine targeting represents a valuable strategy to increase the therapeutic index of active payloads, such as cytokines. On one hand, it allows the selective accumulation of the product at the site of the disease while sparing healthy organs; on the other hand, it may allow the conditional activation of multimeric payloads at the site of the disease.
Bispecific antibodies are an emerging class of potent anti-cancer therapeutics. These molecules often connect relevant tumor-associated antigens to a co-stimulatory receptor (such as CD3), thus aiming to facilitate T-cell activation in the presence of tumor cells expressing the target antigen.
In this Special Issue, we summarise the current state of the art and consider the future perspectives for these therapeutic approaches.
Prof. Anthony Rees
Dr. Alessandra Micaela Villa
Dr. Mattia Matasci
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Cancer immunotherapy
- Immunocytokine (antibody–cytokine fusion)
- Bispecific antibodies
- Conditional activation
- Antibody engineering
